UNLABELLED: Drug-induced liver injury (DILI) is a challenging problem in drug development and clinical practice. Patient susceptibility to DILI is multifactorial, making these reactions difficult to predict and prevent. Clinical observations have suggested that concurrent bacterial and viral infections represent an important risk factor in determining patient susceptibility to developing adverse drug reactions, although the underlying mechanism is not clear. In the present study, we employed the viral RNA mimetic (polyinosinic-polycytidylic acid [polyI:C]) to emulate viral infection and examined its effect on halothane-induced liver injury. Although pretreatment of mice with polyI:C attenuated halothane hepatotoxicity due to its inhibitory effect on halothane metabolism, posttreatment significantly exacerbated liver injury with hepatocellular apoptosis being significantly higher than that in mice treated with polyI:C alone or halothane alone. The pan-caspase inhibitor z-VAD-fmk suppressed liver injury induced by polyI:C/posthalothane cotreatment, suggesting that the increased hepatocyte apoptosis contributes to the exacerbation of liver injury. Posttreatment with polyI:C also caused activation of hepatic Kupffer cells (KCs) and natural killer (NK) cells and upregulated multiple proapoptotic factors, including tumor necrosis factor-alpha (TNF-alpha), NK receptor group 2, member D (NKG2D), and Fas ligand (FasL). These factors may play important roles in mediating polyI:C-induced hepatocyte apoptosis. CONCLUSION: This is the first study to provide evidence that concurrent viral infection can inhibit cytochrome (CYP)450 activities and activate the hepatic innate immune system to proapoptotic factors. DILI may be attenuated or exacerbated by pathogens depending on the time of infection.
UNLABELLED: Drug-induced liver injury (DILI) is a challenging problem in drug development and clinical practice. Patient susceptibility to DILI is multifactorial, making these reactions difficult to predict and prevent. Clinical observations have suggested that concurrent bacterial and viral infections represent an important risk factor in determining patient susceptibility to developing adverse drug reactions, although the underlying mechanism is not clear. In the present study, we employed the viral RNA mimetic (polyinosinic-polycytidylic acid [polyI:C]) to emulate viral infection and examined its effect on halothane-induced liver injury. Although pretreatment of mice with polyI:C attenuated halothane hepatotoxicity due to its inhibitory effect on halothane metabolism, posttreatment significantly exacerbated liver injury with hepatocellular apoptosis being significantly higher than that in mice treated with polyI:C alone or halothane alone. The pan-caspase inhibitor z-VAD-fmk suppressed liver injury induced by polyI:C/posthalothane cotreatment, suggesting that the increased hepatocyte apoptosis contributes to the exacerbation of liver injury. Posttreatment with polyI:C also caused activation of hepatic Kupffer cells (KCs) and natural killer (NK) cells and upregulated multiple proapoptotic factors, including tumor necrosis factor-alpha (TNF-alpha), NK receptor group 2, member D (NKG2D), and Fas ligand (FasL). These factors may play important roles in mediating polyI:C-induced hepatocyte apoptosis. CONCLUSION: This is the first study to provide evidence that concurrent viral infection can inhibit cytochrome (CYP)450 activities and activate the hepatic innate immune system to proapoptotic factors. DILI may be attenuated or exacerbated by pathogens depending on the time of infection.
Authors: George Ostapowicz; Robert J Fontana; Frank V Schiødt; Anne Larson; Timothy J Davern; Steven H B Han; Timothy M McCashland; A Obaid Shakil; J Eileen Hay; Linda Hynan; Jeffrey S Crippin; Andres T Blei; Grace Samuel; Joan Reisch; William M Lee Journal: Ann Intern Med Date: 2002-12-17 Impact factor: 25.391
Authors: Cynthia Ju; Timothy P Reilly; Mohammed Bourdi; Michael F Radonovich; John N Brady; John W George; Lance R Pohl Journal: Chem Res Toxicol Date: 2002-12 Impact factor: 3.739
Authors: Christopher C Franklin; Cecile M Krejsa; Robert H Pierce; Collin C White; Nelson Fausto; Terrance J Kavanagh Journal: Am J Pathol Date: 2002-05 Impact factor: 4.307
Authors: Shubing Liu; David J Gallo; Angela M Green; Debra L Williams; Xiaoyan Gong; Richard A Shapiro; Andrea A Gambotto; Elisabeth L Humphris; Yoram Vodovotz; Timothy R Billiar Journal: Infect Immun Date: 2002-07 Impact factor: 3.441
Authors: Brittany N J Davis; Jeffrey W Santoso; Michaela J Walker; Catherine E Oliver; Michael M Cunningham; Christian A Boehm; Danielle Dawes; Samantha L Lasater; Kim Huffman; William E Kraus; George A Truskey Journal: Ann Biomed Eng Date: 2019-04-08 Impact factor: 3.934
Authors: Y M Ambrosini; G-X Yang; W Zhang; M Tsuda; S Shu; K Tsuneyama; P S C Leung; A A Ansari; R L Coppel; M E Gershwin Journal: Clin Exp Immunol Date: 2011-10 Impact factor: 4.330
Authors: Bin Gao; Ekihiro Seki; David A Brenner; Scott Friedman; Jessica I Cohen; Laura Nagy; Gyongyi Szabo; Samir Zakhari Journal: Am J Physiol Gastrointest Liver Physiol Date: 2011-01-20 Impact factor: 4.052
Authors: Kenneth L Hastings; Martin D Green; Bin Gao; Patricia E Ganey; Robert A Roth; Gary R Burleson Journal: Int J Toxicol Date: 2020 Mar/Apr Impact factor: 2.032